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Abstract
Background: In the global context of a reduction of under-five mortality, neonatal mortality is an increasingly relevant
component of this mortality. Malaria in pregnancy may affect neonatal survival, though no strong evidence exists to
support this association.
Methods: In the context of a randomised, placebo-controlled trial of intermittent preventive treatment (IPTp) with
sulphadoxine-pyrimethamine (SP) in 1030 Mozambican pregnant women, 997 newborns were followed up until 12 months
of age. There were 500 live borns to women who received placebo and 497 to those who received SP.
Findings: There were 58 infant deaths; 60.4% occurred in children born to women who received placebo and 39.6% to
women who received IPTp (p=0.136). There were 25 neonatal deaths; 72% occurred in the placebo group and 28% in the
IPTp group (p=0.041). Of the 20 deaths that occurred in the first week of life, 75% were babies born to women in the
placebo group and 25% to those in the IPTp group (p=0.039). IPTp reduced neonatal mortality by 61.3% (95% CI 7.4%,
83.8%); p=0.024].
Conclusions: Malaria prevention with SP in pregnancy can reduce neonatal mortality. Mechanisms associated with
increased malaria infection at the end of pregnancy may explain the excess mortality in the malaria less protected group.
Alternatively, SP may have reduced the risk of neonatal infections. These findings are of relevance to promote the
implementation of IPTp with SP, and provide insights into the understanding of the pathophysiological mechanisms
through which maternal malaria affects fetal and neonatal health.
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Introduction
Every year over four million babies die in the first four weeks of
life, most of these deaths, - three million - occur in the first week of
life. Of this mortality, 99% take place in developing countries,
where the risk of death in the neonatal period is six times greater
than in developed countries. [1][2,3] With more than 40 neonatal
deaths per 1000 live births, the risk of dying during the neonatal
period is highest in sub-Saharan Africa. [1,2] Lowering child
mortality increasingly depends on tackling neonatal mortality.
Reducing neonatal deaths requires knowing its causes. Globally, it
is estimated that prematurity, infections and asphyxia are the main
direct causes of neonatal death. [3] However, in developing
countries where the majority of these deaths occur, establishing the
causes of neonatal mortality has an inherent uncertainty due to the
limited quality and quantity of the sources of information.
Moreover, few studies, either descriptive or on neonatal
interventions focus on the deaths occurring in low income
countries, and thus, many neonatal deaths still occur without an
obvious cause. [3]
There are little doubts that public health interventions such as
immunization, improved nutrition, water and sanitation have
contributed to child survival
1. However, maternal and neonatal
survival requires additional and specific interventions and
approaches. These should be based on an improved knowledge
of their causes and determinants. [4] Malaria infection during
pregnancy has been mentioned as one of the contributors to
neonatal mortality, mostly through low birth weight (LBW) and by
causing maternal anemia. [5] Although this extrapolation is
probably correct, a direct association between maternal malaria
and neonatal mortality has not yet been confirmed. This
knowledge would help to improve the understanding of the
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on the newborn and infant, as well as to promote the imple-
mentation of preventive interventions.
For malaria stable transmission areas in Africa, where
approximately 25 million pregnancies are exposed every year to
the infection, WHO recommends preventive strategies during
pregnancy. [6] These measures are based on the administration of
intermittent preventive treatment (IPTp) and the use of insecticide
treated nets (ITNs). [6] IPTp consists on the administration of at
least two doses of sulphadoxine-pyrimethamine (SP), regardless of
the presence of parasites. The currently recommended regimen for
IPTp is at least 2 treatment courses of SP given from the 2
nd
trimester onwards at least one month apart.
The uptake of these tools varies between countries but it is still
far from covering the majority of the pregnant women at risk of
malaria in Africa. [7,8,9] To date, there is no confirmatory
evidence from the published malaria prevention trials in
pregnancy of a significant effect of the interventions on infant
survival. [10,11,12,13,14] The lack of conclusive information has
probably affected resource prioritisation for malaria control in
pregnancy in many African countries.
We have recently reported the results on maternal and birth
outcomes of a randomised, double blind, placebo-controlled trial
of IPTp in Mozambican pregnant women (trial registration
number: NCT.00209781). In this trial, it was found that IPTp
with SP was associated with a moderate but significant reduction
in the incidence of clinical malaria during pregnancy, and with a
statistically significant reduction in the prevalence of parasitaemia
at delivery and at 8 weeks postpartum, as well as in fetal anemia in
cord blood. On the other hand, there were no significant
differences in the prevalence of low birth weight, prematurity
nor maternal anemia at delivery between the two groups. [15] The
study also assessed the impact of the intervention on infant’s
survival. Here we present the effect of malaria prevention with
IPTp on survival during the first year of life.
Methods
Ethics Statement
The study protocol was approved by the National Mozambican
Ethics Review Committee, and the Hospital Clinic of Barcelona
Ethics Review Committee. The protocol for this trial and
supporting CONSORT checklist are available as supporting
information; see Checklist S1 and Protocol S1.
Study Area
The study was carried out at the Centro de Investigac ¸a ˜o em
Sau ´de da Manhic ¸a (CISM) in Manhic ¸a District, southern
Mozambique. A demographic surveillance system (DSS) covering
around 80 000 inhabitants is carried out by the CISM and
constitutes the main study area. The demographic and malaria
epidemiological characteristics of the area have been described in
detail elsewhere [16]. Malaria transmission of moderate intensity is
perennial with some seasonality. More than 95% of the malaria
infections are due to P. falciparum. [17] The estimated entomolog-
ical inoculation rate for 2002 was 38 infective bites per person per
year. [18] Data on the efficacy of SP in children in this area
showed a therapeutic efficacy rate of 83%, with an in vivo
parasitological sensitivity of 78.6% at day 14. [19] Adjacent to the
CISM is the Manhic ¸a District Hospital (MDH), a 110 bed health
facility. More than 80% of the deliveries in the area are
institutional. At the time of the study, the prevalence of HIV
infection at the antenatal clinic was 23.6%. [15] Infant (IMR) and
neonatal (NMR) mortality rates for 2005–2006 in the area were 75
and 26 per 1000 live births respectively (Nhacolo A., personal
communication). During the study, malaria control in pregnancy
relied exclusively upon case management. Since October 2005,
the current Mozambican policy to control malaria in pregnant
women is also based on ITNs and IPTp administration.
Study Design and Follow Up
From August 2003 to April 2005, 1030 pregnant women of all
gravidities were enrolled at the MDH into a double blind,
randomised, placebo-controlled trial of two-dose IPTp with SP
(IPTp-SP). Women were randomised to receive three tablets of SP
(1500 mg sulphadoxine/75 mg pyrimetamine) or placebo. At
recruitment all women received a LLITN. The primary objective
of the study was to estimate the additive protective effect of IPTp-
SP to that of ITNs on LBW prevalence. At the time of delivery, the
baby’s birth weight was measured on a digital scale and gestational
age was assessed by the Dubowitz’s method. [20] Maternal
peripheral and cord blood were collected and a placental biopsy
was taken. As an exploratory objective was the assessment of the
impact of the intervention in the mother on the health of the child
during the first year of life.
Maternal, birth outcomes and clinical information up to eight
weeks post delivery have been already reported. [15] After the
code was broken in 2006 two months after the last delivery, the
trial was formally considered unblinded. However, all study
personnel involved in the collection of the trial’s outcomes was not
aware of the participant’s study group.
We present here a full analysis of the effect of the intervention
on infant’s survival up to the last child born to the study women
reached one year of age. Infants were followed up through regular
home visits to assess resident status until the child was one year of
age.
A discrepancy in the number of neonatal deaths with those
already reported [15] was observed when doing the final analysis
once the study followed up was completed. A correction to the
number of deaths has been submitted to the original journal (22
nd
January 2010).
Statistical Methods and Definitions
Neonatal mortality was defined as the death of a live born baby
within the first 28 complete days after birth. Early neonatal
mortality was defined as the death of a baby during the first seven
days of life, while late neonatal mortality referred to deaths
occurring after the 7
th day but before 28 complete days of life. [21]
Infant mortality was defined as deaths occurring during the first 12
months of life. Malaria infection in the placental tissue was
classified as past (presence of malaria pigment only), active
(presence of parasites with or without malaria pigment), and not
infected (neither parasites nor malaria pigment). [22]
Data were analysed by intention-to-treat (ITT) analysis,
whereby infants born to all randomised women were included
regardless of whether or not the mother had received the
intervention during pregnancy and the number of doses taken.
Only live born babies (single and multiple deliveries) were included
in this analysis.
Incidences were calculated using time at risk from date of birth
until date at one year of age, death or withdrawal. Incidences were
expressed as episodes per PYAR where PYAR is Person Years at
Risk. The protective efficacy (PE) of SP was estimated from the
hazard ratio (HR) as PE=100(1-HR)%. Association between risk
factors and death was evaluated using Cox Regression Models
adjusted by the intervention group. Variables for the multivariate
analysis were selected using the backward -stepwise elimination
procedure with a p-value less than 0.05. Differences in proportions
IPT Reduces Neonatal Mortality
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evaluated with the non-parametric Wilcoxon test. Missing values
were categorized as unknown and their proportion was similar in
the two intervention groups. Data analysis was performed using
Stata 10 (Stata Corporation, College Station, TX, USA).
Results
Demographic status at one year of age was documented for 997
of the 1004 live born babies (99%) to the 1030 enrolled pregnant
women (500 were born to women who were in the placebo group
and 497 to women in the IPTp-SP group) (Figure S1). The
number of multiple deliveries was similar between the two groups
(p=0.2).
There were a total of 58 infant deaths. Of them, 35 (60.4%)
(IMR 70 per 1000 live births) were babies born to women who had
received placebo during pregnancy and 23 (39.6%) (IMR 46.3 per
1000 live births) were born to women who had received IPTp-SP
(p=0.136) (Table 1).
There were a total of 25 neonatal deaths. Of them 18 (72%)
(NMR 36 per 1000 live births) babies were born to women in the
placebo group and 7 (28%) (NMR 14 per 1000 live births) were
born to women who had received IPTp-SP (p=0.041) (Table 1).
Of the 25 babies who died within the 28 days after birth, 20
(80%) died within the first week of life (early neonatal mortality).
Of these 20 deaths, 15 (75%) were among babies whose mother
received placebo during pregnancy and 5 (25%) among babies
whose mothers received IPTp-SP (p=0.039) (Table 1). Among the
children who died in the first week of life, mean age at death in
the placebo group was 1.4 days (SD 2.1) compared to 2.8 days in
the SP group (SD 3.0) (p=0.4).
Only nine of the 25 newborns who died in the neonatal period
died at hospital, and the cause of death could be ascertained. In
all, except one, an infectious disease was the most likely cause of
death. Of these, six were children born to women in the placebo
group and two were to those in the IPTp-SP group.
IPTp-SP was associated with a statistically significant reduction
in neonatal mortality [PE 61.3% (95% CI 7.4%, 83.8%);
p=0.024]. The effect of IPTp-SP on neonatal mortality did not
vary by parity [PE 61.9% (95% CI 8.8%, 84.1%); p=0.022] or
HIV infection [PE 62.7% (95% CI 10.5%, 84.4%); p=0.020].
The intervention had a non-statistically significant protective
efficacy in reducing infant mortality by 35.2% [(95% CI 29.6%,
61.7%); p=0.102] (Table 2).
Table 3 presents the univariate Cox regression analysis of the
potential risk factors for neonatal mortality The analysis shows
that low birth weight, prematurity, and the presence of parasites in
placental tissue (active placental infection) or cord blood, were
associated with an increased risk of neonatal death, while IPTp
with SP was associated with a reduction of neonatal mortality. The
multivariate Cox regression analysis adjusted by treatment group
is presented in table 4. In this analysis, the significance of the
association of the variables associated with an increased risk is
maintained, while the effect of IPTp with SP is not longer
statistically significant [Hazard Ratio=0.56 (95% CI 0.22, 1.43) p
value=0.23]. The increased risk for neonatal mortality of the
category of unknowns in some of the variables is likely to reflect
the increased risk associated with delivering outside the health
facility.
Discussion
Almost all (99%) of the 4 million annual neonatal deaths arise in
countries where establishing the causes of death is hampered by
limitations in the quality and quantity of the sources of
information. Causality of neonatal deaths is thus, mainly based
on estimations and most causes of death are unknown. [3] In
endemic countries, maternal malaria has been said to contribute to
neonatal mortality indirectly through low birth weight and
prematurity, though, to our knowledge, no strong evidence exists
to support this association. [5] The results of this randomised,
double blind, placebo-controlled trial showed that, maternal
malaria may have a direct effect on neonatal mortality, and that
prevention of malaria during pregnancy can reduce neonatal
mortality, on average, by 60%. This information is of public health
relevance for malaria endemic countries in Africa, and should
serve to stimulate at national and international levels, the
implementation of malaria prevention strategies in pregnancy,
not only as a measure to reduce low birth weight but also to
directly reduce neonatal mortality.
An effect of malaria prevention in pregnancy on perinatal and
neonatal survival has been suggested previously. Some trials of
malaria preventive strategies in pregnancy (chemoprophylaxis,
IPTp or ITNs), showed individually a trend towards a reduction
in perinatal death or fetal loss, [11,12,23,24,25,26] which became
significant when a meta-analysis was carried out. [27,28] However,
a significant reduction on neonatal deaths was not shown in the
meta-analysis of the three trials reporting this outcome [overall Risk
Ratio 0.68 (95% CI 0.44; 1.05)]. [12,14,23] Two of these trials used
IPTp with SPbutunlikethecurrent studyinwhichITNsweregiven
as part of the study, ITN coverage was low in the other two studies.
[14,23] As it has been suggested for infants, it could be speculated
Table 1. Neonatal and infant mortality by intervention group.
Intervention groups
Placebo+ITNs SP+ITNs Total p
n=500 n=497 n=997
Neonatal mortality (%) (#28 days of life) Alive 482 (96%) 490 (99%) 972 (97%) 0.041
Deaths 18 (4%) 7 (1%) 25 (3%)
Early neonatal mortality (%) (#7 days of life) Alive 485 (97%) 492 (99%) 977 (98%) 0.039
Deaths 15 (3%) 5 (1%) 20 (2%)
Infant mortality (%) (first 12 months of life) Alive 465 (93%) 474 (95%) 939 (94%) 0.136
Deaths 35 (7%) 23 (5%) 58 (6%)
SP=sulphadoxine-pyrimethamine. ITN=insecticide-treated nets.
doi:10.1371/journal.pone.0009438.t001
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Intervention group
Placebo+ITNs SP+ITNs Protective Efficacy
Events PYAR Incidence Events PYAR Incidence % (95% CI) p
Neonatal mortality (#28 days of life) 18 37.3 0.48 7 37.8 0.19 61.3% (7.4%; 83.8%) 0.024
Infant mortality (first 12 months of life) 35 472.0 0.07 23 482.5 0.05 35.2% (29.6%; 61.7%) 0.102
SP=sulphadoxine-pyrimethamine. ITN=insecticide-treated net. PYAR=person-years at risk.
doi:10.1371/journal.pone.0009438.t002
Table 3. Univariate and multivariate analysis of the risk factors for neonatal mortality.
N=970 n % HR (95% CI) p
Placental malaria Not infected 424 43 1.00 0.010
Past infection 321 32 0.82 (0.27–2.52)
Active infection 124 12 3.92 (1.51–10.15)
Unknown 128 13 1.25 (0.33–4.71)
Cord blood parasitaemia No 825 83 1.00 0.005
Yes 9 1 10.93 (2.53–47.34)
Unknown 163 16 1.80 (0.71–4.56)
Low birth weight No 872 87 1.00 ,0.001
(,2500g) Yes 116 12 10.16 (4.46–23.18)
Unknown 9 1 21.76 (4.76–99.35)
Pre-term birth No 907 91 1.00 ,0.001
(,37weeks) Yes 40 4 21.13 (7.66–58.29)
Unknown 50 5 28.09 (10.06–64.67)
Gravidity Primigravidae 256 26 1.00 0.484
1 to 3 pregnancies 395 40 0.57 (0.22–1.49)
4o r.pregnancies 346 35 0.66 (0.25–1.70)
HIV test Negative 645 65 1.00 0.337
Positive 197 20 1.09 (0.43–2.75)
Unknown 155 16 0.23 (0.03–1.72)
RPR Syphilis test Positive 116 12 1.00 0.194
Negative 881 88 0.52 (0.20–1.39)
Literacy Read and/or write 410 41 1.00 0.406
Not read and write 584 59 1.82 (0.76–4.35)
Newborn gender Male 513 51 1.00 0.977
Female 480 48 0.99 (0.45–2.17)
Foetal anaemia No 764 77 1.00 0.325
(PCV,37% in cord blood) Yes 69 7 2.07 (0.60–7.09)
Unknown 164 16 1.76 (0.69–4.49)
Malaria episodes during pregnancy No 908 91 1.00 0.213
Yes 89 9 1.97 (0.68–5.74)
Treatment group in the IPTp trial Placebo 500 50 1.00 0.033
SP 497 50 0.39 (0.16–0.93)
HR=Hazard Ratio. CI=Confidence Interval. p=p-value Fisher’s exact test.
Past infection refers to the presence of malaria pigment but not parasites in the histology.
Active infection refers to acute infection (presence of malaria parasites and minimal pigment) and chronic infection (presence of malaria parasites and pigment) in the
histology.
Unknown HIV test=refused voluntary counselling and testing. RPR test=rapid plasma reagin test.
doi:10.1371/journal.pone.0009438.t003
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current study and these previous two reports might be explained by
the synergistic effect of ITNs and IPTp. [29]
Not surprisingly, most (80%) of the neonatal deaths occurred
within the first week of life. The effect of the intervention on
neonatal survival seemed to be concentrated within this short
period after birth, where two thirds of the deaths occurred among
the babies born to women in the placebo group. The
physiopathological mechanisms that may explain the significant
protective efficacy of two doses of SP given intermittently in
reducing neonatal mortality are not clear. An increase in birth
weight or gestational age is unlikely to be the explanation since
both outcomes were shown to be similar between the two study
groups. [15] On the other hand, the presence of parasites in the
placenta or in cord blood may have had a negative effect on
neonatal survival. IPTp with SP was significantly associated with a
reduced risk of neonatal mortality in the univariate analysis of risk
factors but not in the multivariate model, where placental malaria,
low birth weight, cord blood parasitaemia and pre-term birth had
a stronger association with the risk of death. This indicates that the
effect of the intervention is probably due to a reduction on
placental and cord blood infection as these variables are in the
causal pathway between the effect of the intervention and death.
The local inflammatory reactions associated with active placental
infection may lead to a reduction in the transfer of nutrients to the
foetus, while cord parasitemia may induce fetal anemia and this in
turn may lead to hypoxia, all of which may contribute to neonatal
death. [30] This argument is supported by the finding of fetal
anemia, active placental infection and cord parasitemia more
frequently in the placebo than in the SP group. [15] Thus, it could
be argued that malaria parasitemia in the last weeks of pregnancy
may have a negative direct impact on neonatal survival.
A reduced risk of neonatal infections in the intervention group
due to the antibiotic effect of SP can not be completely ruled out.
It has been reported that infections are an important cause of
neonatal death in developing countries. [31] In this study,
although most neonatal deaths occurred at home, nearly all of
those occurring at the hospital were due to infectious diseases.
However, it seems unlikely that SP was effective against the
infections most frequently occurring during the neonatal period in
this area, mainly Staphilococcus aureus, group B Streptococcus,
and E coli, as it has been shown in this area the low sensitivity of
other sulpha drugs. [32]
In this area, there was a 21% level of in vivo P. falciparum
parasitological resistance to SP in children before this study
started, which could have increased during the course of the study,
thus reducing the efficacy of the drug as antimalarial. [19]
However, the observed efficacy in terms of clinical malaria
protection in the pregnant women was over 70% within the month
after each SP dose. [15] This high clinical efficacy of the
intervention in the pregnant women highlights the difficulties in
extrapolating results from drug efficacy studies in children to
preventive trials and even more in adults. Nonetheless, parasite
resistance to SP has spread across Africa and at some point this
will undermine the efficacy of IPTp-SP. Therefore, research into
new, long half-life antimalarials for IPTp is urgently needed.
In summary, these results confirm a significant effect of malaria
prevention in pregnancy in reducing neonatal mortality. Although
they are based on small numbers, and thus the role of chance can
not be completely ruled out, it can be said that the observed efficacy
of IPTp of over 60% is of relevance for the global initiatives aiming
at reducing the high burden of neonatal and perinatal mortality.
Moreover, the preliminary economic evaluation of this intervention
on neonatal mortality shows a cost effectiveness ratio of just 1.08
USD per DALY averted (Sicuri et al in preparation). Thus, malaria
prevention in pregnancy through IPTp with SP, and probably in
general, may be one of the most cost-effective public health
interventions to reduce neonatal mortality.
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